Park Square Financial Group, LLC Halozyme Therapeutics, Inc. Transaction History
Park Square Financial Group, LLC
- $145 Billion
- Q4 2024
A detailed history of Park Square Financial Group, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Park Square Financial Group, LLC holds 77 shares of HALO stock, worth $4,554. This represents 0.0% of its overall portfolio holdings.
Number of Shares
77Holding current value
$4,554% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
550Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$786 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$425 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$247 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$204 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.24B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...